TROPION-Breast01 Phase III Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Daiichi Sankyo Company, Limited announced that the first patient was dosed in the global TROPION-Breast01 phase III trial evaluating the efficacy and safety of datopotamab deruxtecan in patients with hormone receptor positive, human epidermal growth factor 2 receptor (HER2) negative inoperable or metastatic breast cancer.